Tablet formulation of aqueous leaf extract of Annona muricata and its potential in the management of diabetes

ENGLISH Background: Diabetes mellitus is a chronic and prevalent metabolic disease affecting individuals across all age groups. Studies show that plant-based antidiabetic medications are effective in the management of diabetes. Objectives: The aim of this study was to develop a novel oral tablet formulation from the aqueous leaf extract of Annona muricata (AMALE), evaluate its physico-technical properties and blood glucose lowering capacity. Methods: Powder blends of extract with Avicel ® , corn starch/magnesium carbonate were prepared for direct tablet compression. Flow characteristics and moisture content of the blends were evaluated. Optimized compressed tablets were evaluated for uniformity of weight, hardness, friability and disintegration. Blood glucose lowering capacity of the AMALE and its tablet formulations were investigated in diabetic rats and compared with Glibenclamide. Results: AMALE elicited 79.80% reduction in blood glucose while Glibenclamide showed 68.84% reduction. The combination of AMALE and Glibenclamide gave 56.59% reduction. Powder blend of AMALE, Avicel ® and corn starch was non-hygroscopic and free-flowing. Optimized formulated tablets had uniform weights, moderate hardness (3.78 kgF), low friability (0.17%) and rapid disintegration (2.15 sec). The tablets gave 71.42% reduction in blood glucose with minimal effect on body weight. Conclusion: A unique tablet formulation of AMALE with significant blood glucose lowering potential has been successfully developed. FRANCE Background: Diabetes mellitus is a widespread, chronic metabolic disease affecting people of all ages. Studies show that herbal antidiabetic medications are effective in managing diabetes. Objectives: The aim of this study is to develop a new oral tablet formulation from the aqueous extract of Annona muricata leaves (AMALE), to evaluate its physico-technical properties and its ability to reduce blood glucose. Methods: Powdered extract mixtures with Avicel® and corn starch/magnesium carbonate were prepared for direct tablet compression. The flow characteristics and moisture content of the mixtures were evaluated. The uniformity of weight, hardness, friability, and disintegration of the optimized tablets were assessed. The hypoglycemic capacity of AMALE and its tablet formulations was studied in diabetic rats and compared to that of glibenclamide. Results: AMALE resulted in a 79.80% reduction in blood glucose, while glibenclamide resulted in a 68.84% reduction. The combination of AMALE and glibenclamide resulted in a 56.59% reduction. The mixture of AMALE powder, Avicel®, and corn starch was non-hygroscopic and free-flowing. The optimized formulated tablets had uniform weight, moderate hardness (3.78 kgF), low friability (0.17%), and rapid disintegration (2.15 sec). The tablets resulted in a 71.42% reduction in blood glucose with minimal effect on body weight. Conclusion: A unique AMALE-based tablet formulation with significant potential for blood glucose reduction has been successfully developed.